Pluristem Therapeutics Inc.  

(Public, NASDAQ:PSTI)   Watch this stock  
Find more results for PSTI
1.18
-0.01 (-0.84%)
Real-time:   10:49AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.18 - 1.20
52 week 1.04 - 1.85
Open 1.18
Vol / Avg. 63,865.00/321,133.00
Mkt cap 111.48M
P/E     -
Div/yield     -
EPS -0.33
Shares 96.07M
Beta 0.21
Inst. own 3%
Feb 8, 2017
Q2 2017 Pluristem Therapeutics Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin - -816.51%
Operating margin - -819.07%
EBITD margin - -724.03%
Return on average assets -73.13% -40.75%
Return on average equity -91.40% -48.28%
Employees 169 -
CDP Score - -

Address

Matam Advanced Technology Park Building No. 5
HAIFA, 31905
Israel
+972-74-7108600 (Phone)
+972-74-7108765 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.

Officers and directors

Zalman Aberman Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Yaky Yanay CPA President, Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Doron Shorrer CPA Lead Independent Director
Age: 62
Bio & Compensation  - Reuters
Moria Kwiat Director
Age: 36
Bio & Compensation  - Reuters
Hava Meretzki Director
Age: 46
Bio & Compensation  - Reuters
Israel Ben-Yoram Independent Director
Age: 55
Bio & Compensation  - Reuters
Issac Braun Independent Director
Age: 63
Bio & Compensation  - Reuters